Operational Highlights and Financial Results for the Period Ended December 31, 2021
24 févr. 2022 17h30 HE
|
Mesoblast Limited
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
Mesoblast Corporate Update and Financial Results Webcast
24 févr. 2022 05h57 HE
|
Mesoblast Limited
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy
20 févr. 2022 18h19 HE
|
Mesoblast Limited
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from...
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
01 févr. 2022 19h20 HE
|
Mesoblast Limited
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment...
Appendix 4C Quarterly Activity Report
30 janv. 2022 19h16 HE
|
Mesoblast Limited
NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and...
Mesoblast to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022
24 janv. 2022 18h45 HE
|
Mesoblast Limited
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in...
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
11 janv. 2022 20h26 HE
|
Mesoblast Limited
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced 36-month follow-up...
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
30 déc. 2021 18h38 HE
|
Mesoblast Limited
Key Points: Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC)...
FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program
15 déc. 2021 19h09 HE
|
Mesoblast Limited
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received...
Update on Novartis Agreement
13 déc. 2021 19h18 HE
|
Mesoblast Limited
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it...